This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Coghlan, J G Articles by Handler, C Search for Related Content PubMed PubMed Citation Articles by Coghlan, J G Articles by Handler, C Pubmed/NCBI databases Medline Plus Health Information Connective Tissue Disorders Pulmonary Hypertension Social Bookmarking                   What's this?

Connective tissue associated pulmonary arterial hypertension

Department of Cardiology, Royal Free Hospital, London, UK, Gerry.Coghlan{at}royalfree.nhs.uk

C Handler

Department of Cardiology, Royal Free Hospital, London, UK

The number of publications in the field of pulmonary hypertension has increased exponentially over the past 10 years. As a consequence our understanding of the condition has advanced enormously. Pulmonary hypertension is now recognised as an uncommon and treatable disease, rather than a rare lethal disease. Progress in the field of connective tissue disease associated pulmonary hypertension has been less consistent. This paper covers the most influential published data on connective tissue associated pulmonary hypertension, and adds some insights from data available on file with pharmaceutical companies and from our database at the Royal Free Hospital. The following conclusions may be drawn. First, the prevalence of pulmonary hypertension associated with connective tissue diseases is lower than generally accepted. Second, the natural history and prognosis, at least in the setting of systemic sclerosis, is worse than seen in patients with idiopathic pulmonary hypertension. Finally, widespread and timely availability of disease modifying therapies substantially improves the prognosis for patients with systemic sclerosis associated pulmonary hypertension, in the treatment population and consequentially in the population as a whole. Identifying patients with very early disease and analysing the drivers for disease progression, is the key to further progress. Early diagnosis is most readily achieved in patients with connective tissue disease associated pulmonary hypertension. This represents an opportunity for those with an interest in academic rheumatology.

Key Words: connective tissue disease • disease modifying therapy • natural history • pathophysiology • prevalence • pulmonary arterial hypertension • systemic sclerosis

Lupus, Vol. 15, No. 3, 138-142 (2006)
DOI: 10.1191/0961203306lu2280rr


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H M A Hofstee, A V. Noordegraaf, A E Voskuyl, B A C Dijkmans, P E Postmus, Y M Smulders, and E H Serne Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis Ann Rheum Dis, February 1, 2009; 68(2): 191 - 195. [Abstract] [Full Text] [PDF]

				D. M. Meads, S. P. McKenna, N. Doughty, C. Das, W. Gin-Sing, J. Langley, and J. Pepke-Zaba The responsiveness and validity of the CAMPHOR Utility Index Eur. Respir. J., December 1, 2008; 32(6): 1513 - 1519. [Abstract] [Full Text] [PDF]

				C P Denton, J E Pope, H-H Peter, A Gabrielli, A Boonstra, F H J van den Hoogen, G Riemekasten, S De Vita, A Morganti, M Dolberg, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases Ann Rheum Dis, September 1, 2008; 67(9): 1222 - 1228. [Abstract] [Full Text] [PDF]

				J. G. Coghlan and C. E. Handler N-terminal brain natriuretic peptide in scleroderma-associated pulmonary arterial hypertension: reply Eur. Heart J., January 1, 2007; 28(1): 141 - 141. [Full Text] [PDF]